About Adze

Oncolytic Immunotherapies

Adze Biotechnology is a pre-clinical stage company developing a portfolio of systemically deliverable oncolytic immunotherapies for the treatment of cancers with significant unmet needs.

Adze Biotechnology has exclusive licenses to oncolytic immunotherapies developed in the lab of Dr Michael Barry of Mayo Clinic.

Adze has generated a strong preclinical dataset, and is actively involved in partnering conversations with biotech and pharma companies to speed our assets to the clinic.

Adze solves key problems in Cancer immunotherapy

Checkpoint inhibitors (CPIs) comprise a $28+ billion market

However, there are four major shortcomings with CPIs:

CPIs don’t kill cancer cells directly. CPIs merely “release the brakes” on a patient’s CD8+ T cells, which then kill cancer cells.
T cells often cannot specifically recognize cancer cells to kill them.
T cell function often becomes impaired due to factors in the tumor microenvironment.
T cells often can’t infiltrate many types of tumors. These are referred to as ‘cold’ tumors.

Adze oncolytic immunotherapies solves these problems by:

Killing cancer cells directly, while releasing tumor neoantigens.
Allowing T cells to recognize cancer cells via the released neoantigens.
Delivering immune stimulatory payloads to stimulate T cell function.
Generating markers of immunogenic cell death which increases T cells infiltration in tumors (turning ‘cold’ tumors ‘hot’).